.png)
Transthyretin Amyloidosis (ATTR) Market By Disease (Transthyretin (TTR) Familial Amyloid Cardiomyopathy, Transthyretin (TTR) Familial Amyloid Polyneuropathy, and Others), Treatment (RNAi Therapy, Small Molecules Treatment, Organ Transplantation and Others) and End-User (Ambulatory Surgical Centers, Hospitals And Clinics and Others) - Global Industry Analysis And Forecast To 2027
Published On : August 2018 Pages : 180 Category: Pharmaceuticals Report Code : HC081225
SEGMENTS & REGIONS:
- By Disease: Transthyretin (TTR
- Transthyretin: TTR
- Treatment: RNAi Therapy, Small Molecules Treatment, Organ Transplantation and Others
- User: Ambulatory Surgical Centers, Hospitals And Clinics and Others
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Industry Outlook
The Transthyretin Amyloidosis (ATTR) Market is anticipated to grow tremendously over the forecast period. Transthyretin (TTR) amyloidosis is a medical condition portrayed by the development of irregular deposits of a protein called amyloid (amyloidosis) in a body's organs and tissues. It commonly influences the cardiovascular system and peripheral neuropathic or autonomic neuropathy system. The cardiovascular type of Transthyretin (TTR) amyloidosis brings about the risk of cardiomegaly, arrhythmia and orthostatic hypertension in patients. The worldwide ATTR market is anticipated to display a powerful development amid the conjecture time frame because of the likelihood of rising launches of ATTR therapeutic drugs, expanding African-American populace as they are hereditarily vulnerable to amyloidosis, expanding healthcare awareness among individuals, and increasing average income of people. Nonetheless, the development of this market can be impeded by stringent administrative schemes, the rising expense of ATTR drugs and inaccurate analysis of ATTR disorders and confinements of clinical trials.
Market Segmentation
The Transthyretin Amyloidosis (ATTR) market is based on different segments namely by disease the market is segmented into transthyretin (ttr) familial amyloid cardiomyopathy, transthyretin (ttr) familial amyloid polyneuropathy, and others; by treatment the market is segmented into rnai therapy, small molecules treatment, organ transplantation and others; by end-user the market is segment into ambulatory surgical centers, hospitals and clinics and others.
- Transthyretin Amyloidosis (ATTR) Market By Disease
- Transthyretin (TTR) Familial Amyloid Cardiomyopathy
- Transthyretin (TTR) Familial Amyloid Polyneuropathy
- Others
- Transthyretin Amyloidosis (ATTR) Market By Treatment
- RNAi Therapy
- Small Molecules Treatment
- Organ Transplantation
- Others
- Transthyretin Amyloidosis (ATTR) Market By End User
- Ambulatory Surgical Centers
- Hospitals And Clinics
- Others
Regional Insights
On a global front, the Transthyretin Amyloidosis (ATTR) Market covers North America (United States, Canada and Mexico), Europe (Germany, UK, France, Russia, Italy, Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific), South America (Brazil, Argentina, Columbia, South Africa, Rest of South America) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA). The Americas command the market for Transthyretin (TTR) amyloidosis due to the rising prevalence of amyloidosis among adults and elderly population and increasing geriatric population which is a significant trigger factor for this disease.
- Transthyretin Amyloidosis (ATTR) Market, By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The leading players in the market are Merck & Co, Corino Therapeutics Inc, Proclara Biosciences, Pfizer, Arcturus Therapeutics, Alnylam Pharmaceuticals and Ionis Pharmaceuticals. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Merck & Co
- Corino Therapeutics Inc
- Proclara Biosciences
- Pfizer
- Arcturus Therapeutics
- Alnylam Pharmaceuticals
- Ionis Pharmaceuticals
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Transthyretin Amyloidosis (ATTR) Market, By Disease, Estimates and Forecast, 2017-2027 ($Billion)
o Transthyretin (TTR) Familial Amyloid Cardiomyopathy
o Transthyretin (TTR) Familial Amyloid Polyneuropathy
o Others
· Transthyretin Amyloidosis (ATTR) Market, By Treatment, Estimates and Forecast, 2017-2027 ($Billion)
o RNAi Therapy
o Small Molecules Treatment
o Organ Transplantation
o Others
· Transthyretin Amyloidosis (ATTR) Market, By End User, Estimates and Forecast, 2017-2027 ($Billion)
o Ambulatory Surgical Centers
o Hospitals And Clinics
o Others
· Transthyretin Amyloidosis (ATTR) Market, By Region, Estimates and Forecast, 2017-2027 ($Billion)
o North America
§ North America Transthyretin Amyloidosis (ATTR) Market, By Country
o U.S. Transthyretin Amyloidosis (ATTR) Market
o Canada Transthyretin Amyloidosis (ATTR) Market
o Mexico Transthyretin Amyloidosis (ATTR) Market
o Europe
§ Europe Transthyretin Amyloidosis (ATTR) Market, By Country
o Germany Transthyretin Amyloidosis (ATTR) Market
o UK Transthyretin Amyloidosis (ATTR) Market
o France Transthyretin Amyloidosis (ATTR) Market
o Russia Transthyretin Amyloidosis (ATTR) Market
o Italy Transthyretin Amyloidosis (ATTR) Market
o Rest of Europe Transthyretin Amyloidosis (ATTR) Market
o Asia-Pacific
§ Asia-Pacific Transthyretin Amyloidosis (ATTR) Market, By Country
o China Transthyretin Amyloidosis (ATTR) Market
o Japan Transthyretin Amyloidosis (ATTR) Market
o South Korea Transthyretin Amyloidosis (ATTR) Market
o India Transthyretin Amyloidosis (ATTR) Market
o Southeast Asia Transthyretin Amyloidosis (ATTR) Market
o Rest of Asia-Pacific Transthyretin Amyloidosis (ATTR) Market
o South America
§ South America Transthyretin Amyloidosis (ATTR) Market
o Brazil Transthyretin Amyloidosis (ATTR) Market
o Argentina Transthyretin Amyloidosis (ATTR) Market
o Columbia Transthyretin Amyloidosis (ATTR) Market
o Rest of South America Transthyretin Amyloidosis (ATTR) Market
o Middle East and Africa
§ Middle East and Africa Transthyretin Amyloidosis (ATTR) Market
o Saudi Arabia Transthyretin Amyloidosis (ATTR) Market
o UAE Transthyretin Amyloidosis (ATTR) Market
o Egypt Transthyretin Amyloidosis (ATTR) Market
o Nigeria Transthyretin Amyloidosis (ATTR) Market
o South Africa Transthyretin Amyloidosis (ATTR) Market
o Rest of MEA Transthyretin Amyloidosis (ATTR) Market
Table of Contents
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market States and Outlook (2017-2027)
4.1.2. Canada Market States and Outlook (2017-2027)
4.1.3. Mexico Market States and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market States and Outlook (2017-2027)
4.2.2. France Market States and Outlook (2017-2027)
4.2.3. UK Market States and Outlook (2017-2027)
4.2.4. Russia Market States and Outlook (2017-2027)
4.2.5. Italy Market States and Outlook (2017-2027)
4.2.6. Rest of Europe Market States and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market States and Outlook (2017-2027)
4.3.2. Japan Market States and Outlook (2017-2027)
4.3.3. Korea Market States and Outlook (2017-2027)
4.3.4. India Market States and Outlook (2017-2027)
4.3.5. Southeast Asia Market States and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market States and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market States and Outlook (2017-2027)
4.4.2. Argentina Market States and Outlook (2017-2027)
4.4.3. Columbia Market States and Outlook (2017-2027)
4.4.4. Rest of South America Market States and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market States and Outlook (2017-2027)
4.5.2. United Arab Emirates Market States and Outlook (2017-2027)
4.5.3. Egypt Market States and Outlook (2017-2027)
4.5.4. Nigeria Market States and Outlook (2017-2027)
4.5.5. South Africa Market States and Outlook (2017-2027)
4.5.6. Turkey Market States and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market States and Outlook (2017-2027)
5. Transthyretin Amyloidosis (ATTR) Market, By Disease
5.1. Introduction
5.2. Global Transthyretin Amyloidosis (ATTR) Revenue and Market Share by Disease (2017-2027)
5.2.1. Global Transthyretin Amyloidosis (ATTR) Revenue and Revenue Share by Disease (2017-2027)
5.3. Transthyretin (TTR) Familial Amyloid Cardiomyopathy
5.3.1. Global Transthyretin (TTR) Familial Amyloid Cardiomyopathy Revenue and Growth Rate (2017-2027)
5.4. Transthyretin (TTR) Familial Amyloid Polyneuropathy
5.4.1. Global Transthyretin (TTR) Familial Amyloid Polyneuropathy Revenue and Growth Rate (2017-2027)
5.5. Others
5.5.1. Global Others Revenue and Growth Rate (2017-2027)
6. Transthyretin Amyloidosis (ATTR) Market, By Treatment
6.1. Introduction
6.2. Global Transthyretin Amyloidosis (ATTR) Revenue and Market Share by Treatment (2017-2027)
6.2.1. Global Transthyretin Amyloidosis (ATTR) Revenue and Revenue Share by Treatment (2017-2027)
6.3. RNAi Therapy
6.3.1. Global RNAi Therapy Revenue and Growth Rate (2017-2027)
6.4. Small Molecules Treatment
6.4.1. Global Small Molecules Treatment Revenue and Growth Rate (2017-2027)
6.5. Organ Transplantation
6.5.1. Global Organ Transplantation Revenue and Growth Rate (2017-2027)
6.6. Others
6.6.1. Global Others Revenue and Growth Rate (2017-2027)
7. Transthyretin Amyloidosis (ATTR) Market, By End-User
7.1. Introduction
7.2. Global Transthyretin Amyloidosis (ATTR) Revenue and Market Share by End-User (2017-2027)
7.2.1. Global Transthyretin Amyloidosis (ATTR) Revenue and Revenue Share by End-User (2017-2027)
7.3. Ambulatory Surgical Centers
7.3.1. Global Ambulatory Surgical Centers Revenue and Growth Rate (2017-2027)
7.4. Hospitals
7.4.1. Global Hospitals Revenue and Growth Rate (2017-2027)
7.5. Clinics
7.5.1. Global Clinics Revenue and Growth Rate (2017-2027)
7.6. Others
7.6.1. Global Others Revenue and Growth Rate (2017-2027)
8. Transthyretin Amyloidosis (ATTR) Market, By Region
8.1. Introduction
8.2. Global Transthyretin Amyloidosis (ATTR) Revenue and Market Share by Regions
8.2.1. Global Transthyretin Amyloidosis (ATTR) Revenue by Regions (2017-2027)
8.3. North America Transthyretin Amyloidosis (ATTR) by Countries
8.3.1. North America Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2027)
8.3.2. North America Transthyretin Amyloidosis (ATTR) Revenue (Million USD) by Countries (2017-2027)
8.3.3. United States
8.3.3.1. United States Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.4. Canada
8.3.4.1. Canada Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.5. Mexico
8.3.5.1. Mexico Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.4. Europe Transthyretin Amyloidosis (ATTR) by Countries
8.4.1. Europe Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2027)
8.4.2. Europe Transthyretin Amyloidosis (ATTR) Revenue (Million USD) by Countries (2017-2027)
8.4.3. Germany
8.4.3.1. Germany Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.4. France
8.4.4.1. France Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.5. UK
8.4.5.1. UK Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.6. Russia
8.4.6.1. Russia Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.7. Italy
8.4.7.1. Italy Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.8. Rest of Europe
8.4.8.1. Rest of Europe Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.5. Asia-Pacific Transthyretin Amyloidosis (ATTR) by Countries
8.5.1. Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2027)
8.5.2. Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue (Million USD) by Countries (2017-2027)
8.5.3. China
8.5.3.1. China Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.4. Japan
8.5.4.1. Japan Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.5. Korea
8.5.5.1. Korea Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.6. India
8.5.6.1. India Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.7. Southeast Asia
8.5.7.1. Southeast Asia Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.8. Rest of Asia-Pacific
8.5.8.1. Rest of Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.6. South America Transthyretin Amyloidosis (ATTR) by Countries
8.6.1. South America Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2027)
8.6.2. South America Transthyretin Amyloidosis (ATTR) Revenue (Million USD) by Countries (2017-2027)
8.6.3. Brazil
8.6.3.1. Brazil Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.4. Argentina
8.6.4.1. Argentina Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.5. Columbia
8.6.5.1. Columbia Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.6. Rest of South America
8.6.6.1. Rest of South America Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.7. Middle East and Africa Transthyretin Amyloidosis (ATTR) by Countries
8.7.1. Middle East and Africa Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2027)
8.7.2. Middle East and Africa Transthyretin Amyloidosis (ATTR) Revenue (Million USD) by Countries (2017-2027)
8.7.3. Saudi Arabia
8.7.3.1. Saudi Arabia Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.4. United Arab Emirates
8.7.4.1. United Arab Emirates Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.5. Egypt
8.7.5.1. Egypt Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.6. Nigeria
8.7.6.1. Nigeria Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.7. South Africa
8.7.7.1. South Africa Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.8. Turkey
8.7.8.1. Turkey Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.9. Rest of Middle East and Africa
8.7.9.1. Rest of Middle East and Africa Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
9. Company Profiles
9.1. Merck & Co
9.1.1. Business Overview
9.1.2. Service Portfolio
9.1.3. Strategic Developments
9.1.4. Revenue and Market Share
9.2. Corino Therapeutics Inc
9.2.1. Business Overview
9.2.2. Service Portfolio
9.2.3. Strategic Developments
9.2.4. Revenue and Market Share
9.3. Proclara Biosciences
9.3.1. Business Overview
9.3.2. Service Portfolio
9.3.3. Strategic Developments
9.3.4. Revenue and Market Share
9.4. Pfizer
9.4.1. Business Overview
9.4.2. Service Portfolio
9.4.3. Strategic Developments
9.4.4. Revenue and Market Share
9.5. Arcturus Therapeutics
9.5.1. Business Overview
9.5.2. Service Portfolio
9.5.3. Strategic Developments
9.5.4. Revenue and Market Share
9.6. Alnylam Pharmaceuticals
9.6.1. Business Overview
9.6.2. Service Portfolio
9.6.3. Strategic Developments
9.6.4. Revenue and Market Share
9.7. Ionis Pharmaceuticals
9.7.1. Business Overview
9.7.2. Service Portfolio
9.7.3. Strategic Developments
9.7.4. Revenue and Market Share
10. Global Transthyretin Amyloidosis (ATTR) Market Competition, by Manufacturer
10.1. Global Transthyretin Amyloidosis (ATTR) Revenue and Market Share by Manufacturer (2017-2017)
10.2. Global Transthyretin Amyloidosis (ATTR) Price By Region (2017-2017)
10.3. Top 5 Transthyretin Amyloidosis (ATTR) Manufacturer Market Share
10.4. Market Competition Trend
11. Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.1. Global Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2027)
11.2. Transthyretin Amyloidosis (ATTR) Market Forecast by Regions (2017-2027)
11.2.1. North America Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.1.1. United States Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.1.2. Canada Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.1.3. Mexico Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.2. Europe Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.2.1. Germany Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.2.2. France Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.2.3. UK Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.2.4. Russia Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.2.5. Italy Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.2.6. Rest of Europe Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.3. Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.3.1. China Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.3.2. Japan Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.3.3. Korea Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.3.4. India Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.3.5. Southeast Asia Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.3.6. Rest of Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.4. South America Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.4.1. Brazil Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.4.2. Argentina Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.4.3. Columbia Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.4.4. Rest of South America Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.5. Middle East and Africa Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.5.1. Saudi Arabia Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.5.2. United Arab Emirates Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.5.3. Egypt Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.5.4. Nigeria Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.5.5. South Africa Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.5.6. Turkey Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.2.5.7. Rest of Middle East and Africa Transthyretin Amyloidosis (ATTR) Market Forecast (2017-2027)
11.3. Transthyretin Amyloidosis (ATTR) Market Forecast by Disease (2017-2027)
11.3.1. Transthyretin Amyloidosis (ATTR) Forecast by Disease (2017-2027)
11.3.2. Transthyretin Amyloidosis (ATTR) Market Share Forecast by Disease (2017-2027)
11.4. Transthyretin Amyloidosis (ATTR) Market Forecast by Treatment (2017-2027)
11.4.1. Transthyretin Amyloidosis (ATTR) Forecast by Treatment (2017-2027)
11.4.2. Transthyretin Amyloidosis (ATTR) Market Share Forecast by Treatment (2017-2027)
11.5. Transthyretin Amyloidosis (ATTR) Market Forecast by End-User (2017-2027)
11.5.1. Transthyretin Amyloidosis (ATTR) Forecast by End-User (2017-2027)
11.5.2. Transthyretin Amyloidosis (ATTR) Market Share Forecast by End-User (2017-2027)
List of Tables
12. List of Tables and Figures
Figure United States Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Transthyretin Amyloidosis (ATTR) Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Transthyretin Amyloidosis (ATTR) Revenue and Revenue Share by Disease (2017-2018)
Figure Global Transthyretin (TTR) Familial Amyloid Cardiomyopathy Revenue and Growth Rate (2017-2018)
Figure Global Transthyretin (TTR) Familial Amyloid Polyneuropathy Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Transthyretin Amyloidosis (ATTR) Revenue and Revenue Share by Treatment (2017-2018)
Figure Global RNAi Therapy Revenue and Growth Rate (2017-2018)
Figure Global Small Molecules Treatment Revenue and Growth Rate (2017-2018)
Figure Global Organ Transplantation Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Transthyretin Amyloidosis (ATTR) Revenue and Revenue Share by End-User (2017-2018)
Figure Global Ambulatory Surgical Centers Revenue and Growth Rate (2017-2018)
Figure Global Hospitals Revenue and Growth Rate (2017-2018)
Figure Global Clinics Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Transthyretin Amyloidosis (ATTR) Revenue by Regions (2017-2018)
Figure North America Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure North America Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2018)
Figure North America Transthyretin Amyloidosis (ATTR) by Countries (2017-2018)
Figure North America Transthyretin Amyloidosis (ATTR) Revenue (Million USD) by Countries (2017-2018)
Figure United States Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure United States Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Canada Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Mexico Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Europe Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2018)
Figure Europe Transthyretin Amyloidosis (ATTR) by Countries (2017-2018)
Figure Europe Transthyretin Amyloidosis (ATTR) Revenue (Million USD) by Countries (2017-2018)
Figure Germany Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Germany Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure France Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure UK Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Russia Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Italy Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Rest of Europe Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Transthyretin Amyloidosis (ATTR) by Countries (2017-2018)
Figure Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue (Million USD) by Countries (2017-2018)
Figure China Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure China Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Japan Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Korea Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure India Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Southeast Asia Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure South America Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2018)
Figure South America Transthyretin Amyloidosis (ATTR) by Countries (2017-2018)
Figure South America Transthyretin Amyloidosis (ATTR) Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Brazil Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Argentina Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Columbia Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Rest of South America Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Middle East and Africa Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Transthyretin Amyloidosis (ATTR) by Countries (2017-2018)
Figure Middle East and Africa Transthyretin Amyloidosis (ATTR) Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Saudi Arabia Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure United Arab Emirates Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Egypt Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Nigeria Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure South Africa Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Turkey Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Transthyretin Amyloidosis (ATTR) Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2017-2018)
Table Merck & Co Transthyretin Amyloidosis (ATTR) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Corino Therapeutics Inc Transthyretin Amyloidosis (ATTR) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Proclara Biosciences Transthyretin Amyloidosis (ATTR) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Pfizer Transthyretin Amyloidosis (ATTR) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Transthyretin Amyloidosis (ATTR) Market Share by Manufacturer
Figure Global Transthyretin Amyloidosis (ATTR) Revenue and Market Share by Manufacturer
Table Global Transthyretin Amyloidosis (ATTR) Price by Region (2017-2017)
Figure Top 5 Transthyretin Amyloidosis (ATTR) Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Transthyretin Amyloidosis (ATTR) Revenue (Millions USD) and Growth Rate (2018-2025)
Table Transthyretin Amyloidosis (ATTR) Market Forecast by Regions (2018-2025)
Figure North America Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure United States Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Canada Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Mexico Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Europe Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Germany Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure France Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure UK Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Russia Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Italy Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Rest of Europe Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure China Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Japan Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Korea Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure India Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Southeast Asia Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure South America Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Brazil Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Argentina Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Columbia Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Rest of South America Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Middle East and Africa Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Saudi Arabia Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure United Arab Emirates Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Egypt Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Nigeria Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure South Africa Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Turkey Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Transthyretin Amyloidosis (ATTR) Market Forecast (2018-2025)
Figure Global Transthyretin Amyloidosis (ATTR) Forecast by Disease (2018-2025)
Figure Global Transthyretin Amyloidosis (ATTR) Market Share Forecast by Disease (2018-2025)
Figure Global Transthyretin Amyloidosis (ATTR) Forecast by Disease (2018-2025)
Figure Global Transthyretin Amyloidosis (ATTR) Forecast by Treatment (2018-2025)
Figure Global Transthyretin Amyloidosis (ATTR) Market Share Forecast by Treatment (2018-2025)
Figure Global Transthyretin Amyloidosis (ATTR) Forecast by Treatment (2018-2025)
Figure Global Transthyretin Amyloidosis (ATTR) Forecast by End-User (2018-2025)
Figure Global Transthyretin Amyloidosis (ATTR) Market Share Forecast by End-User (2018-2025)
Figure Global Transthyretin Amyloidosis (ATTR) Forecast by End-User (2018-2025)
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|